Second primary malignancy after radical prostatectomy in a cohort from the Middle East

dc.contributor.authorShahait, Mohammed
dc.contributor.authorMukherji, Deborah M.
dc.contributor.authorHamieh, Nadine M.
dc.contributor.authorNassif, Samer R.
dc.contributor.authorJabbour, Mark N.
dc.contributor.authorKhauli, Raja Bahjat
dc.contributor.authorBulbul, Muhammad Ahmad
dc.contributor.authorAbou-Kheir, Wassim G.
dc.contributor.authorEl Hajj, Albert Elias
dc.contributor.departmentSurgery
dc.contributor.departmentDivision of Urology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:12:54Z
dc.date.available2025-01-24T12:12:54Z
dc.date.issued2018
dc.description.abstractBackground: Data from the Middle East regarding second primary malignancy (SPM) after radical prostatectomy are limited. Our objective was to estimate the overall risk of developing second primary malignancy (SPM) among Middle Eastern men with prostate cancer who underwent surgical extirpation of their prostate. Materials and methods: We conducted a retrospective study of 406 patients who underwent radical prostatectomy in a tertiary centre and who had no evidence of previous malignancy from 1998 to 2012. Standardized incidence ratios (SIRs) and 95% confidence interval (CI) were calculated to analyze the risk of SPM in our population compared with the general population. Cox-regression models were also conducted to correlate the clinicopathological factors with the development of SPM. Results: After 14 years of follow-up, the incidence rate of SPM was 100.9 per 1,000 person-years. The most frequent SPMs were bladder cancer (n = 11, 27%) followed by hematological malignancies (n = 9, 22%) and lung cancer (n = 7, 17%). The overall risk for men with prostate cancer to develop SPM is lower than the men in the general population (standardized incidence ratios = 0.19; 95% CI: 0.14–0.25). A multivariate analysis failed to correlate any of the clinicopathological factors with the development of SPM. Conclusion: Patients with prostate cancer who underwent surgical expiration of their prostate are at lower risk of developing SPM compared with the general population. © 2017
dc.identifier.doihttps://doi.org/10.1016/j.prnil.2017.09.002
dc.identifier.eid2-s2.0-85036632505
dc.identifier.urihttp://hdl.handle.net/10938/32919
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofProstate International
dc.sourceScopus
dc.subjectProstate cancer
dc.subjectRadical prostatectomy
dc.subjectSecond primary malignancies
dc.subjectStandardized incidence ratios
dc.subjectProstate specific antigen
dc.subjectAdult
dc.subjectArticle
dc.subjectBiochemical recurrence
dc.subjectBladder cancer
dc.subjectCancer diagnosis
dc.subjectCancer incidence
dc.subjectCancer radiotherapy
dc.subjectCancer risk
dc.subjectCancer surgery
dc.subjectCohort analysis
dc.subjectControlled study
dc.subjectCorrelational study
dc.subjectFollow up
dc.subjectHuman
dc.subjectIncidence
dc.subjectMajor clinical study
dc.subjectMale
dc.subjectMiddle aged
dc.subjectMiddle east
dc.subjectPriority journal
dc.subjectProstatectomy
dc.subjectSecond cancer
dc.subjectStandardized incidence ratio
dc.subjectSurgical margin
dc.subjectTertiary care center
dc.titleSecond primary malignancy after radical prostatectomy in a cohort from the Middle East
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2018-4266.pdf
Size:
305.06 KB
Format:
Adobe Portable Document Format

Collections